Patents by Inventor Lakmali ATAPATTU

Lakmali ATAPATTU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11160873
    Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: November 2, 2021
    Assignees: Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd., Olivia Newton-John Cancer Research Institute
    Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
  • Patent number: 10676712
    Abstract: A process for producing a 3D tissue culture model by (a) printing a drop of bio-ink to a substrate; (b) printing a drop of activator to the drop of bio-ink to form a hydrogel droplet; (c) repeating steps (a) and (b) in any order to form a hydrogel mold adapted to receive a drop containing cells; (d) printing a drop containing cells to the hydrogel mold; and (e) repeating steps (a) and (b) in any order to form a 3D tissue culture model comprising the cells encapsulated in the hydrogel mold.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: June 9, 2020
    Assignee: Inventia Life Science Pty Ltd
    Inventors: Aidan Patrick O'Mahony, Robert Hadinoto Utama, Christopher Michael Fife, Lakmali Atapattu, Julio Cesar Caldeira Ribeiro, Maria Kavallaris, John Justin Gooding
  • Publication number: 20190105405
    Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
    Type: Application
    Filed: July 5, 2018
    Publication date: April 11, 2019
    Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
  • Publication number: 20180230423
    Abstract: A process for producing a 3D tissue culture model by (a) printing a drop of bio-ink to a substrate; (b) printing a drop en.) of activator to the drop of bio-ink to form a hydrogel droplet; (c) repeating steps (a) and (b) in any order to form a hydrogel mold adapted to receive a drop containing cells; (d) printing a drop containing cells to the hydrogel mold; and (e) repeating steps (a) and (b) in any order to form a 3D tissue culture model comprising the cells encapsulated in the hydrogel mold.
    Type: Application
    Filed: July 21, 2016
    Publication date: August 16, 2018
    Applicant: Inventia Life Science Pty Ltd
    Inventors: Aidan Patrick O'MAHONY, Robert Hadinoto UTAMA, Christopher Michael FIFE, Lakmali ATAPATTU, Julio Cesar Caldeira RIBEIRO, Maria KAVALLARIS, John Justin GOODING
  • Patent number: 10023653
    Abstract: Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumor cells that also express the putative tumor stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumor cells and also as a therapeutic agent for treating cancers, tumors and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumor, renal tumor, prostate cancer, sarcoma and/or melanoma.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: July 17, 2018
    Assignees: Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd.
    Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
  • Publication number: 20170008976
    Abstract: Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
    Type: Application
    Filed: February 4, 2015
    Publication date: January 12, 2017
    Inventors: Martin LACKMANN, Peter W. JANES, Lakmali Atapattu MUDIYANSELAGE, Andrew M. SCOTT, Dimitar B. NIKOLOV, Nayanendu SAHA